Biofrontera opened at $0.94, in line with its previous close of $0.94. In the last trading session, the stock traded between $0.91 and $0.94. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Biofrontera is now worth
$ 1.35
Resulting in a loss of
$ 98.65 (98.65%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.01 (-1.01%)
Day High
$0.94
Day Low
$0.91
Day Open
$0.94
Prev Close
$0.94
Volume
1,29,411
1W Return
2.65%
1M Return
-0.32%
3M Return
-23.68%
6M Return
-16.40%
1Y Return
-10.77%
Fundamentals
Market Cap ($ Mn)
14
PE Ratio
-
PB Ratio
3.78
PEG Ratio
-
ROE
-647.73%
ROCE
-140.90%
EPS (TTM)
$-0.04
Investment Returns
1 Week
2.65%
1 Month
-0.32%
3 Months
-23.68%
6 Months
-16.40%
9 Months
20.54%
Financials
Quarterly
All values in $ Mn
8.6
Mar 25
9.0
Jun 25
7.0
Sep 25
17.1
Dec 25
10.1
Mar 26
12.0
Jun 26
Updates
7Nov
Biofrontera Inc Q3FY27 Results: Earnings release scheduled for Nov 13
Biofrontera Inc. will report Q3 2026 results on November 13, 2026. Conference call scheduled for 10:00 am Eastern Time on the same day. Company focuses on photodynamic therapy for dermatological conditions.
6 days ago
8Oct
Biofrontera files sNDA to expand Ameluz for full-body actinic keratoses
Biofrontera Inc. filed an sNDA with the FDA to expand Ameluz indication to actinic keratoses on extremities, neck, and trunk. Phase 3 trial showed **45.6%** complete clearance rate for Ameluz PDT versus **16.7%** for vehicle control. **86.3%** of patients indicated they would choose PDT again, citing favorable tolerability with the new illumination protocol. Company reported revenue growth of **12%** in FY25 and **25%** in H1 2026, expecting further acceleration from label expansions.
1mo ago
28Sep
Biofrontera Q2 revenue up 33% to $12 million as EBITDA nears breakeven
Net product revenue rose 33% YoY to $12 million in Q2 2026. Gross margin expanded to approximately 80% from 71% in Q2 2025. Adjusted EBITDA improved to negative $0.2 million from negative $5.1 million. Ameluz unit volume grew 30% YoY to 33,300 tubes. Cash position stands at $4.7 million with going concern qualification disclosed.
1mo ago
14Sep
Biofrontera secures FDA approval for Ameluz to treat skin cancer
Biofrontera secured FDA approval for Ameluz PDT to treat superficial basal cell carcinoma. Ameluz becomes the first and only PDT drug approved by FDA for treating skin cancer. Phase 3 trial showed 66% primary endpoint achievement vs 5% for placebo. Launch planned for late Q4 2026 through Q1 2027 using existing commercial infrastructure.
